Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13770
Country/Region: Ethiopia
Year: 2016
Main Partner: Harari Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,132,139 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $81,872
Care: TB/HIV (HVTB) $96,320
Care: Pediatric Care and Support (PDCS) $34,290
Laboratory Infrastructure (HLAB) $43,344
Strategic Information (HVSI) $24,796
Health Systems Strengthening (OHSS) $38,528
Biomedical Prevention: Blood Safety (HMBL) $12,825
Testing: HIV Testing and Counseling (HVCT) $40,267
Sexual Prevention: Other Sexual Prevention (HVOP) $11,455
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $75,840
Treatment: Adult Treatment (HTXS) $642,598
Treatment: Pediatric Treatment (PDTX) $30,004
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 30
GEND_GBV Number of people receiving post-GBV care 2017 50
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,634
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,701
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 25,382
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 11,630
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 40,347
HTS_TST Service Delivery Point (Facility): Inpatient 2017 3,085
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,052
HTS_TST Service Delivery Point (Facility): Outpatient 2017 11,822
HTS_TST Service Delivery Point (Facility): PMTCT 2017 14,649
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,315
HTS_TST Service Delivery Point (Facility): VCT 2017 6,424
HTS_TST Sum of Aggregated Age/Sex <15 2017 3,335
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 37,012
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 40,347
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 15
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 19
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 189
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 91
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 360
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 360
KP_PREV Total estimated number of key population in the catchment area 2017 582
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 582
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 3
LAB_PT CD4: Number of laboratories that perform this testing 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 9
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 9
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 9
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 9
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
PMTCT_ART Already on ART at beginning of current pregnancy 2017 78
PMTCT_ART New on ART 2017 29
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 13,055
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 81
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 21
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 1
PMTCT_EID Sum of Infant Age disaggregates 2017 102
PMTCT_STAT By: Known positives at entry 2017 96
PMTCT_STAT By: Number of new positives identified 2017 20
PMTCT_STAT Number of new ANC and L&D clients 2017 14,063
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 13,055
PMTCT_STAT Sum of Positives Status disaggregates 2017 116
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,096
PP_PREV Total number of people in the target population 2017 1,316
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 26
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 32
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 67
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 67
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 252
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 78
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 74
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 100
TB_SCREENDX Screen Result: Screened Positive for TB 2017 359
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 2,176
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 1,118
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 141
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 149
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 3,584
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 31
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 204
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 43
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 259
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 537
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 551
TX_CURR Aggregated Age/Sex: <15 Female 2017 51
TX_CURR Aggregated Age/Sex: <15 Male 2017 44
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,016
TX_CURR Aggregated Age/Sex: 15+ Male 2017 605
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 1,716
TX_CURR Sum of Aggregated Age/Sex <15 2017 95
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 1,621
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 1,716
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 9
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 10
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 94
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 56
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 169
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 169
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1,114
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 891
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 27
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 24
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 527
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 313
TX_PVLS Numerator: Indication: Routine 2017 713
TX_PVLS Numerator: Indication: Targeted 2017 178
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 35
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 29
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 660
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 390
TX_PVLS_den Denominator: Indication: Routine 2017 892
TX_PVLS_den Denominator: Indication: Targeted 2017 222
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 58
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 33
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 99
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 109
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 35
Cross Cutting Budget Categories and Known Amounts Total: $127,938
Food and Nutrition: Policy, Tools, and Service Delivery $10,643
Renovation $98,713
Key Populations: Sex Workers $4,582
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $14,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation